
Sun Pharma can now launch Leqselvi in the US
Sun Pharmaceuticals Industries Ltd on Thursday, April 10 said the US Court of Appeals for the Federal Circuit has ruled in favour of the company and vacated its preliminary injunction of delaying the launch of Leqselvi (deuruxolitinib), effective immediately.
The medication is intended for treating severe alopecia areata.
Sun Pharma said it will disclose its launch plans in due course of time.
Quicklinks